Page last updated: 2024-12-06

1,2,3,6,7,8-hexachlorodibenzodioxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

1,2,3,6,7,8-hexachlorodibenzodioxin, more commonly known as **2,3,7,8-TCDD** or simply **dioxin**, is a highly toxic chemical that belongs to a group of compounds called **dioxins**. It's a byproduct of various industrial processes and can be found in the environment.

**Here's why 2,3,7,8-TCDD is important for research:**

* **Extremely toxic:** It's one of the most toxic chemicals known, with significant adverse effects on human health.
* **Persistent in the environment:** Dioxins don't easily break down and can accumulate in the food chain, posing long-term risks.
* **Causes various health problems:** Exposure to dioxins is linked to cancer, reproductive and developmental problems, immune suppression, and endocrine disruption.
* **Understanding its mechanisms:** Researchers study dioxins to understand how they interact with biological systems, their mechanisms of toxicity, and their long-term effects on human health.
* **Developing countermeasures:** Research into dioxins helps develop methods to minimize their production and release into the environment, as well as strategies for cleanup and remediation.
* **Risk assessment and management:** Studying dioxins enables scientists to assess and manage the risks associated with their presence in the environment and develop effective public health policies.

**Current research focuses on:**

* **Identifying and characterizing dioxin-related health effects:** This includes studying different exposure levels and their corresponding impacts on various organs and systems.
* **Understanding the mechanisms of dioxin toxicity:** Researchers are investigating how dioxins interact with cellular pathways, leading to their toxic effects.
* **Developing new analytical methods:** Researchers are working on more sensitive and efficient methods to detect and measure dioxins in the environment and in biological samples.
* **Developing new strategies for remediation:** This involves finding effective ways to remove dioxins from contaminated sites and reduce their presence in the environment.

Overall, 2,3,7,8-TCDD and other dioxins are a significant environmental and public health concern. Research into these compounds is crucial for understanding their toxicity, mitigating their effects, and protecting human health.

1,2,3,6,7,8-hexachlorodibenzodioxin: contaminant of pentachlorophenol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID42540
CHEBI ID81503
SCHEMBL ID5967950
MeSH IDM0135531

Synonyms (29)

Synonym
1,2,3,6,7,8-hexachlorodibenzo-p-dioxin
dibenzo-p-dioxin, 1,2,3,6,7,8-hexachloro-
1,2,3,6,7,8-hexachlorodibenzodioxin
1,2,3,6,7,8-hxcdd
1,2,3,6,7,8-hexachlorodibenzo(b,e)(1,4)dioxin
1,2,3,6,7,8-hcdd/1,2,3,7,8,9-hcdd
brn 1627652
1,2,3,6,7,8-hexachlorodibenzo-para-dioxin
ccris 323
nci-c03703
hsdb 4154
dibenzo(b,e)(1,4)dioxin, 1,2,3,6,7,8-hexachloro-
1,2,3,6,7,8-hexachlorooxanthrene
57653-85-7
C18101
pcdd 67
FT-0669145
b94l7a4g3d ,
unii-b94l7a4g3d
hexachlorodibenzo-p-dioxin, 1,2,3,6,7,8-
1,2,3,6,7,8-hexachlorodibenzo-p-dioxin [hsdb]
CHEBI:81503
SCHEMBL5967950
YCLUIPQDHHPDJJ-UHFFFAOYSA-N
1,2,3,6,7,8-hexachloro-p-dioxin
DTXSID0023824
Q26841237
1,2,3,6,7,8-hexa-chlorodibenzo-p-dioxin
dibenzo(b,e)(1,4)dioxin,hexachloro

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The mixture was constituted such that each of the congeners contributed one fourth to total toxic equivalency."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. I. Design, general observations, hematology,and liver concentrations.
Birnbaum, LS; Kettrup, A; Rozman, KK; Schramm, KW; Stahl, BU; Viluksela, M, 1998
)
0.3
" This study supports the validity of the toxic equivalency factor (TEF) method and the notion of additive toxicity for CDDs as currently used in the risk assessment of these compounds."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.
Birnbaum, LS; Rozman, KK; Stahl, BU; Viluksela, M, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. I. Design, general observations, hematology,and liver concentrations.
Birnbaum, LS; Kettrup, A; Rozman, KK; Schramm, KW; Stahl, BU; Viluksela, M, 1998
)
0.3
" The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.
Birnbaum, LS; Rozman, KK; Stahl, BU; Viluksela, M, 1998
)
0.3
" The slopes of the dose-response curves generated by individual PCDDs and/or their mixture were similar."( Toxic equivalency factors of polychlorinated dibenzo-p-dioxins in an ovulation model: validation of the toxic equivalency concept for one aspect of endocrine disruption.
Gao, X; Rozman, KK; Son, DS; Terranova, PF, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polychlorinated dibenzodioxineAny dibenzodioxine in which two or more hydrogens have been replaced by chlorines.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (20.00)18.7374
1990's4 (26.67)18.2507
2000's6 (40.00)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]